Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 5-6, 2010, Pages 564-568

  Bao, Yu Qian ^a,b,c   Zhou, Jian ^a,b,c   Zhou, Mi ^a,b,c   Cheng, Yi Jia ^a,b,c   Lu, Wei ^a,b,c   Pan, Xiao Ping ^a,b,c   Tang, Jun Ling ^a,b,c   Lu, Hui Juan ^a,b,c   Jia, Wei Ping ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Diabetes Institute   (China)

^c Shanghai Key Laboratory of Diabetes Mellitus   (China)

Author keywords

Continuous glucose monitoring; Glycaemic variability; Type 2 diabetes

Indexed keywords

ACARBOSE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED ALBUMIN; GLYCOSYLATED HEMOGLOBIN; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL; INSULIN; TABLET;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANALYSIS; BLOOD; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; REGRESSION ANALYSIS; TABLET; TREATMENT OUTCOME;

ACARBOSE; ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLIPIZIDE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; TABLETS; TREATMENT OUTCOME;

EID: 77951127375     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05361.x     Document Type: Article

References (32)

1. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. JAMA 2006 295 : 1681 1687.
2. Ceriello A. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 2005 54 : 1 7.
3. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem. 2004 279 : 42351 42354.
4. Praet SF, Manders RJ, Meex RC et al. Glycaemic instability is an underestimated problem in Type II diabetes. Clin. Sci. 2006 111 : 119 126.
5. Maia FF, Araujo LR. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res. Clin. Pract. 2007 75 : 30 4.
6. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 1994 17 : 1460 1464.
7. Leaf E, King JO. Patient outcomes after formulary conversion from immediate-release to extended-release glipizide tablets. Am. J. Health Syst. Pharm. 1999 56 : 454 456.
8. Hara T, Nakamura J, Koh N, Sakakibara F, Takeuchi N, Hotta N. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996 19 : 642 647.
9. Go EH, Kyriakidou-Himonas M, Berelowitz M. Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with Type 2 diabetes. Diabetes Metab. Res. Rev. 2004 20 : 225 231.
10. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for Type 2 diabetes. South. Med. J. 2002 95 : 68 71.
11. Rosak C, Haupt E, Walter T, Werner J. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: Additive blood glucose lowering effect and decreased hypoglycemia. Diabetes Nutr. Metab. 2002 15 : 143 151.
12. World Health Organization. Diagnosis and Classification of Diabetes Mellitus. In : World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. World Health Organization
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 419.
14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2004 27 : S5 10.
15. Zhou J, Li H, Ran X et al. Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care 2009 32 : 1188 1193.
16. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970 19 : 644 655.
17. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: A further measure of diabetic instability. Diabetologia 1972 8 : 342 348.
18. McCall AL, Cox DJ, Crean J, Gloster M, Kovatchev BP. A novel analytical method for assessing glucose variability: Using CGMS in type 1 diabetes mellitus. Diabetes Technol. Ther. 2006 8 : 644 653.
19. The DECODE Study Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999 354 : 617 621.
20. Muggeo M, Zoppini G, Bonora E et al. Fasting plasma glucose variability predicts 10-year survival of Type 2 diabetic patients: The Verona Diabetes Study. Diabetes Care 2000 23 : 45 50.
21. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000 23 : 1830 1834.
22. Tanenberg R, Bode B, Lane W et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: A randomized controlled trial. Mayo Clin. Proc. 2004 79 : 1521 1526.
23. De Mattia G, Laurenti O, Moretti A. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: Results of a pilot study. Acta Diabetol. 2009 46 : 67 73.
24. Zhou J, Jia W, Bao Y et al. Glycemic variability and its responses to intensive insulin treatment in newly diagnosed Type 2 diabetes. Med. Sci. Monit. 2008 14 : CR552 8.
25. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997 20 : 597 606.
26. Defronzo RA. Pharmacologic therapy for Type 2 diabetes mellitus. Ann. Intern. Med. 1999 131 : 281 303.
27. Chung M, Kourides I, Canovatchel W, Sutfin T, Messig M, Chaiken RL. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate release glipizide in patients with Type II diabetes mellitus. J. Clin. Pharmacol. 2002 42 : 651 657.
28. McCulloch DK, Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition. Diabetes Care 1983 6 : 483 487.
29. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in Type 2 diabetic patients: A randomized crossover study. J. Clin. Endocrinol. Metab. 2006 91 : 837 842.
30. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: Epidemiological perspectives. Int. J. Clin. Pract. Suppl. 2002 129 : 5 11.
31. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004 47 : 385 394.
32. Gao Y, Li G, Li Y et al. Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50. Int. J. Clin. Pract. 2008 62 : 1344 1351.